Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Vertex Pharmaceuticals Incorporated”

980 pharma patents match "Vertex Pharmaceuticals Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 980
Index total 30,257
Page 11 / 41

Quick answer

This filtered view shows 980 pharmaceutical patents matching "Vertex Pharmaceuticals Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

980 results for “Vertex Pharmaceuticals Incorporated” · 30,257 patents in full index Clear search

  1. US 9340546

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted May 17, 2016 · Expires May 12, 2036

    granted

  2. US 9340557

    Substituted quinoxaline DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted May 17, 2016 · Expires May 12, 2036

    granted

  3. US 9334244

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted May 10, 2016 · Expires May 5, 2036

    granted

  4. US 9321725

    Processes for producing cycloalkylcarboxamido-pyridine benzoic acids

    Vertex Pharmaceuticals Incorporated · Granted Apr 26, 2016 · Expires Apr 21, 2036

    granted

  5. US 9314455

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

    Vertex Pharmaceuticals Incorporated · Granted Apr 19, 2016 · Expires Apr 14, 2036

    granted

  6. US 9309250

    Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted

  7. US 9296701

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Mar 29, 2016 · Expires Mar 24, 2036

    granted

  8. US 9254291

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Feb 9, 2016 · Expires Feb 4, 2036

    granted

  9. US 9249131

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Feb 2, 2016 · Expires Jan 28, 2036

    granted

  10. US 9241934

    Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof

    Vertex Pharmaceuticals Incorporated · Granted Jan 26, 2016 · Expires Jan 21, 2036

    granted

  11. US 9216969

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Dec 22, 2015 · Expires Dec 17, 2035

    granted

  12. US 9193722

    Tri-cyclic pyrazolopyridine kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Nov 24, 2015 · Expires Nov 19, 2035

    granted

  13. US 9192606

    Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

    Vertex Pharmaceuticals Incorporated · Granted Nov 24, 2015 · Expires Nov 19, 2035

    granted

  14. US 9181273

    Morpholine-spirocyclic piperidine amides as modulators of ion channels

    Vertex Pharmaceuticals Incorporated · Granted Nov 10, 2015 · Expires Nov 5, 2035

    granted

  15. US 9163042

    Prodrugs of pyridone amides useful as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Oct 20, 2015 · Expires Oct 15, 2035

    granted

  16. US 9156880

    Prodrug of an ice inhibitor

    Vertex Pharmaceuticals Incorporated · Granted Oct 13, 2015 · Expires Oct 8, 2035

    granted

  17. US 9150552

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

    Vertex Pharmaceuticals Incorporated · Granted Oct 6, 2015 · Expires Oct 1, 2035

    granted

  18. US 9139529

    Substituted quinoxalines as sodium channel modulators

    Vertex Pharmaceuticals Incorporated · Granted Sep 22, 2015 · Expires Sep 17, 2035

    granted

  19. US 9139530

    Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

    Vertex Pharmaceuticals Incorporated · Granted Sep 22, 2015 · Expires Sep 17, 2035

    granted

  20. US 9137973

    Pyrazolopyridine kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Sep 22, 2015 · Expires Sep 17, 2035

    granted

  21. US 9125922

    Phosphate esters of gyrase and topoisomerase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Sep 8, 2015 · Expires Sep 3, 2035

    granted

  22. US 9120790

    Azaindoles useful as inhibitors of Janus kinases

    Vertex Pharmaceuticals Incorporated · Granted Sep 1, 2015 · Expires Aug 27, 2035

    granted

  23. US 9108903

    Amides as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Aug 18, 2015 · Expires Aug 13, 2035

    granted

  24. US 9102672

    Azaindole derivatives as CFTR modulators

    Vertex Pharmaceuticals Incorporated · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.